News

EVMS and ODU join forces to create state’s largest health sciences program

Old Dominion University and Eastern Virginia Medical School are joining forces in an effort to grow local medical talent where there’s a great public need.

Together EVMS and ODU are now the Macon and Joan Brock Virginia Health Sciences at ODU.

The merger creates the largest health sciences program in the Commonwealth.

Come July 1, the integration will develop a larger pipeline for healthcare professionals in Hampton Roads by attracting and retaining homegrown talent and doubling the number of residency slots.

“All you’ve heard today is to better the community, better health care in the region,” said EVMS President Alfred Abuhamad, “so this is why there’s tremendous excitement on campus with EVMS about coming together with ODU.”

A 10-year agreement with ODU, EVMS and Sentara provides $350 million in total support for the new academic health sciences center. The merger expands healthcare capabilities while reducing disparities in Hampton Roads.

A $20 million endowment from the Ellmer family and a $20 million endowment from the Brock family will provide scholarships for local students who want to go into health sciences but are held back by financial hardship. ODU’s School of Nursing and College of Health Sciences were renamed the Ellmer School of Nursing and Ellmer College of Health Sciences.

“Those scholarships are encouraging students to stay and be here,” said ODU President Brian Hemphill. “Their residencies, our students that are going into nursing and physical therapy, we want them here.”

The integrated Virginia Health Sciences program will collectively serve 5,000 students.

 

Read more here.

Recent News

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …